Assyro AI

FDA Orange Book · active-ingredient family

Rauwolfia serpentina root

Rauwolfia serpentina root is approved as 11 brand and 8 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:HIWOLFIA · NDA 009276

11

Brand (NDA)

8

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
HIWOLFIA×3BOWMAN PHARMSNDA 009276Approved Prior to Jan 1, 1982
HYSERPINPHYS PRODS VANDA 010581Approved Prior to Jan 1, 1982
KOGLUCOID×2PANRAYNDA 009278Approved Prior to Jan 1, 1982
RAUDIXIN×2APOTHECONNDA 008842Approved Prior to Jan 1, 1982
RAUSERPIN×2FERNDALE LABSNDA 009926Approved Prior to Jan 1, 1982
RAUVAL×2PAL PAKNDA 009108Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINA×2BUNDYNDA 009477Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINA×2IMPAX LABSNDA 009273Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINA×2IVAX SUB TEVA PHARMSNDA 011521Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINA×2VALEANT PHARM INTLNDA 009668Approved Prior to Jan 1, 1982
WOLFINA×2FOREST PHARMSNDA 009255Approved Prior to Jan 1, 1982

Generic (ANDA) products (8)

ProductApplicantApplicationTEApproved
RAUWOLFIA SERPENTINA×2HALSEYANDA 080498Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINA×2PUREPAC PHARMANDA 080842Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINA×2PVT FORMANDA 080583Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINA×2SOLVAYANDA 080500Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINATABLICAPSANDA 083867Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINATABLICAPSANDA 083444Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINAWATSON LABSANDA 080907Approved Prior to Jan 1, 1982
RAUWOLFIA SERPENTINAWATSON LABSANDA 080914Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Rauwolfia serpentina root — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.